Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Risk factors for candidaemia: A prospective multi-centre case-control study

Loading...
Thumbnail Image

Date

Authors

Keighley, C.
Pope, Alun
Marriott, Deborah J. E.
Chapman, Belinda
Bak, Narin
Daveson, Kathryn
Hajkowicz, K
Halliday, Catriona
Kennedy, Karina
Kidd, Sarah E

Journal Title

Journal ISSN

Volume Title

Publisher

Blackwell Publishing Inc.

Abstract

Objectives Candidaemia carries a mortality of up to 40% and may be related to increasing complexity of medical care. Here, we determined risk factors for the development of candidaemia. Methods We conducted a prospective, multi-centre, case-control study over 12 months. Cases were aged ≥18 years with at least one blood culture positive for Candida spp. Each case was matched with two controls, by age within 10 years, admission within 6 months, admitting unit, and admission duration at least as long as the time between admission and onset of candidaemia. Results A total of 118 incident cases and 236 matched controls were compared. By multivariate analysis, risk factors for candidaemia included neutropenia, solid organ transplant, significant liver, respiratory or cardiovascular disease, recent gastrointestinal, biliary or urological surgery, central venous access device, intravenous drug use, urinary catheter and carbapenem receipt. Conclusions Risk factors for candidaemia derive from the infection source, carbapenem use, host immune function and organ-based co-morbidities. Preventive strategies should target iatrogenic disruption of mucocutaneous barriers and intravenous drug use

Description

Citation

Source

Mycoses

Book Title

Entity type

Access Statement

License Rights

Restricted until

2099-12-31